mRESVIA

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

NLC India is seeking 1,500 acres of private land for utility-scale solar projects in Tamil Nadu, implying around 300 MW of initial capacity with potential expansion to roughly 600 MW under a green-shoe option. Representative image.

PowerBank (NASDAQ: PBK) clears permit for C$14m Nova Scotia solar project

Continental Resources is expanding its Permian Basin footprint through the acquisition of FireBird Energy II, adding about 54,000 net Midland Basin acres and 32,000 barrels of oil equivalent per day of production, including a 69% oil mix. Representative image.

Continental Resources to buy FireBird as Permian footprint grows more than 40%

Mitsubishi Electric Corporation’s $1.4 billion acquisition of PCI Energy Solutions expands its push into power-market software as utilities manage increasingly complex grids shaped by renewables, battery storage and rising electricity demand. Representative image.

Mitsubishi Electric’s $1.4bn PCI deal targets software managing 60% of US power

Johan Sverdrup crude could meet 25% of ORLEN demand under three-year agreement

Equinor strikes three-year ORLEN deal for up to 9m tonnes of crude a year

Representative image: A healthcare professional prepares an RSV vaccine dose as researchers expand adult immunization strategies following the U.S. Food and Drug Administration’s approval allowing GSK plc’s Arexvy RSV vaccine to be used in at-risk adults aged 18 to 49.

GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market

FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
ZYNRELEF
Zynga

March 15, 2026